RxDoctor Payments Data

Dennis McGowan, MD

Orthopaedic Surgery · Kearney, NENPI 1598855298

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medical Device Business Services, Inc. at 29.4% of the total. Reporting peaked in 2023 at $3,605 and has fallen 55.6% since, to $1,601 in 2025.

$10,824in general payments, 2019–2025

Across 91 payments — averaging $118.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$3K
  • Osteonovus, Inc.$2K
  • Centinel Spine, LLC$1K
  • Orthofix Medical, Inc.$902
  • Curvafix, Inc.$822
  • Johnson & Johnson$687
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$8758%
  • Travel & lodging$5,26649%
  • Food & beverage$4,61443%
  • Entertainment$691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,824 in reported general payments places this provider in the 75th percentile of 155 orthopaedic surgery providers in Nebraska.

See all orthopaedic surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$176,978
Medicare patients
184
Services billed
4,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide12$20,851
EliquisApixaban17$12,898
XareltoRivaroxaban18$9,711
Dabigatran EtexilateDabigatran Etexilate Mesylate17$2,602
Gabapentin94$1,413
Celecoxib66$1,276
Bumetanide16$464
SotalolSotalol Hcl19$229
Chlorthalidone19$162
Amlodipine Besylate14$128
Metoprolol Tartrate11$56
Losartan Potassium13$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$687$9,71118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 155 orthopaedic surgery providers in Nebraska.

Other orthopaedic surgery in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →